Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 6/20 | 1.00 |
| ▸ | FABP3 | P05413 | 5/20 | 1.00 |
| ▸ | PRNP | P04156 | 1/20 | 0.71 |
| ▸ | PPARG | P37231 | 1/20 | 0.71 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.71 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.71 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.71 |
| ▸ | FABP5 | Q01469 | 5/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.65 |
| ▸ | DHODH | Q02127 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAP2 | P11137 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2820951 | 0.90 | FABP4 (0.82) | FABP4FABP3PRNPPPARGRXFP1 | |
| SCHEMBL10659362 | 0.88 | FABP4 (0.79) | FABP4FABP3PRNPPPARGRXFP1 | |
| SCHEMBL3322903 | 0.85 | FABP4 (0.73) | FABP4FABP3PRNPPPARGRXFP1 | |
| SCHEMBL14916797 | 0.84 | FABP4 (0.73) | FABP4FABP3PRNPPPARGRXFP1 | |
| SCHEMBL3318172 | 0.84 | FABP4 (0.72) | FABP4FABP3PRNPPPARGRXFP1 | |
| SCHEMBL12497003 | 0.83 | FABP4 (0.71) | FABP4FABP3PRNPPPARGRXFP1 | |
| SCHEMBL14917093 | 0.83 | FABP4 (1.00) | FABP4FABP3PRNPPPARGRXFP1 | |
| SCHEMBL27658279 | 0.82 | GAA (0.77) | FABP4FABP3PRNPPPARGRXFP1 | |
| SCHEMBL3322283 | 0.82 | FABP4 (0.69) | FABP4FABP3PRNPPPARGRXFP1 | |
| SCHEMBL8132130 | 0.81 | FABP4 (0.68) | FABP4FABP3PRNPPPARGRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116761598-A | Antiviral use of FABP4 modulating compounds | 新月生物科学 | 2023-09-15 | — | — | CN | claimed |
| US-20230255933-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | CRESCENTA BIOSCIENCES (US) | 2023-08-17 | — | — | US | claimed |
| US-20230241025-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | CRESCENTA BIOSCIENCES (US) | 2023-08-03 | — | — | US | claimed |
| EP-4175647-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | Crescenta Biosciences (US) | 2023-05-10 | — | — | EP | claimed |
| WO-2022010951-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | CRESCENTA BIOSCIENCES (US) | 2022-01-13 | — | — | WO | claimed |
| US-12138243-B2 | Antiviral use of FABP4 modulating compounds | CRESCENTA BIOSCIENCES (US) | 2024-11-12 | — | — | US | disclosed |
| CN-116761598-A | Antiviral use of FABP4 modulating compounds | 新月生物科学 | 2023-09-15 | — | — | CN | disclosed |
| US-20230255933-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | CRESCENTA BIOSCIENCES (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230241025-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | CRESCENTA BIOSCIENCES (US) | 2023-08-03 | — | — | US | disclosed |
| EP-4175647-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | Crescenta Biosciences (US) | 2023-05-10 | — | — | EP | disclosed |
| US-11229624-B2 | FABP4 as a therapeutic target in skin diseases | TICURE LTD. (IL) | 2022-01-25 | — | — | US | disclosed |
| WO-2022010951-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | CRESCENTA BIOSCIENCES (US) | 2022-01-13 | — | — | WO | disclosed |
| US-20200138779-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | TICURE LTD. (IL) | 2020-05-07 | — | — | US | disclosed |
| US-20190201376-A1 | Method for Treating or Preventing Fatty Acid Binding Protein 3 Induced B-amyloid Aggregation Diseases | NATIONAL TAIWAN NORMAL UNIVERSITY (TW) | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241025-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | FABP1, FABP4, FABP5 | FABP4 2/4885FABP3 4/4885PRNP 2761/4885 |
| US-12138243-B2 | Antiviral use of FABP4 modulating compounds | FABP1, FABP5, FABP4 | FABP4 3/4885FABP3 4/4885PRNP 1487/4885 |
| US-11229624-B2 | FABP4 as a therapeutic target in skin diseases | FABP4, FABP2, FABP1 | FABP4 1/4885FABP3 5/4885PRNP 4562/4885 |
| US-20200138779-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | FABP4, FABP2, FABP1 | FABP4 1/4885FABP3 5/4885PRNP 4562/4885 |
| US-20230255933-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | FABP1, FABP4, FABP5 | FABP4 2/4885FABP3 4/4885PRNP 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.